1. Home
  2. KXIN vs OGEN Comparison

KXIN vs OGEN Comparison

Compare KXIN & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$4.54

Market Cap

3.3M

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.85

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
OGEN
Founded
2015
1996
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
OGEN
Price
$4.54
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
85.5K
Earning Date
01-01-0001
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$0.82
52 Week High
$75.00
$18.90

Technical Indicators

Market Signals
Indicator
KXIN
OGEN
Relative Strength Index (RSI) 62.52 37.57
Support Level $3.51 $0.85
Resistance Level $4.93 $0.89
Average True Range (ATR) 0.83 0.06
MACD -0.05 0.00
Stochastic Oscillator 46.37 7.19

Price Performance

Historical Comparison
KXIN
OGEN

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About OGEN Oragenics Inc.

Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.

Share on Social Networks: